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Abstract
Reasons behind the rapid increase of thyroid cancer (TC) in China are uncertain. We
assessed the burden of TC and the role of access to screening and salt iodization. We
analyzed two national databases in China: Hospital Quality Monitoring System
(HQMS) and China Reinsurance Company (CRC) database. HQMS covered 1037
(44.3%) Class 3 hospitals and 76 263 617 Class 3 hospital inpatients in 2013 to 2017
and CRC covered 93 123 018 clients in 2000 to 2016. The proportion of TC inpa-
tients among inpatients in HQMS and TC incidence in critical illness insurance buyers
were used to evaluate the association with screening and iodine status. Between
2013 and 2017, the proportion of TC patients in HQMS with urban employee medi-
cal insurance and good access to screening increased sharply while there was little
change among those with the other two forms of medical insurance. Across prov-
inces, the proportion of TC inpatients in HQMS was positively correlated with per
capita disposable income but not with median urinary iodine. Similar findings were
observed in the CRC database. In 2017, approximately 1000 individuals were over-
diagnosed with TC daily. We conservatively forecast that 5.1 million healthy individ-
uals would become TC patients unnecessarily between 2019 and 2030. Our findings
suggested the epidemic of TC in China was substantially underestimated. It was asso-
ciated with screening but not with salt iodization.
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1 | INTRODUCTION
The incidence of thyroid cancer (TC) had increased rapidly worldwide
in recent decades.1 Since 1975, the incidence in the United States
had increased from 4.9/100 000 to 14.3/100 000 in 2009.2 In South
Korea, the incidence of TC in 2011 was 15 times that observed in
1993 though mortality rates had remained unchanged.3 TC had also
become the fastest growing malignancy in China, with the annual per-
centage change (APC) of the incidence in women rising from 4.9% in
2000 to 2003 to 20.1% in 2003 to 2011.4 According to a national
report published by National Cancer Center of China, the estimated
incidence in 2014 was 12.40/100 000.5
Screening leads to increased detection of asymptomatic TC
lesions.6-8 Thyroid nodules were found in 68% of asymptomatic peo-
ple by high-resolution ultrasound examination in Germany.9 About 7%
to 15% of thyroid nodules were malignant.10 A national screening pro-
gram was initiated for cancer and other common diseases in South
Korea in 1999, and the incidence of TC rapidly increased since then.3
However, a sharp fall was observed since a physician coalition advo-
cated the stopping of screening in 2014.11 In the United States, high-
income counties experienced more rapid increases in incidence than
low-income counties since 1975. People with higher incomes were
exposed to increased health check intensity.7 In the past decade, the
government of China initiated reforms to achieve universal access to
health care. From 2003 to 2011, social medical insurance coverage
increased from 29.7% to 95.7%.12 There are three types of insurance:
rural medical insurance (RMI), urban resident medical insurance
(URMI) and urban employee medical insurance (UEMI). The odds of
regular health checks among those with UEMI was 52% higher com-
pared to those with URMI and RMI because employers often offer
annual general health checks as incentives to their staff.13 However,
the role of TC screening as part of regular health checks in explaining
the rapid growth of TC in China has not been studied.
Another factor that has been named as a potential factor behind
the increase in occurrence of TC in China is iodine intake.14 China
used to be an iodine-deficient country, with a high prevalence of
iodine deficiency disorders (IDDs).15 Since 1996, universal salt
iodization was introduced in China as a mandatory policy.16 With the
rapid increase of TC in recent years, its possible role had aroused
much public concern.17,18
Using two large national databases involving inpatients and com-
mercial critical illness insurance (CII) buyers, we studied the associa-
tion of the access to screening and salt iodization on the rapid growth
of TC. We also estimated the current incidence and the disease bur-
den of TC in China.
2 | MATERIALS AND METHODS
2.1 | Data sources
Hospital Quality Monitoring System (HQMS) is a mandatory patient-
level national database for hospital accreditation under the auspice of
the National Health Commission. Since 2013, the Commission has
requested Class 3 hospitals in China to submit standardized electronic
inpatient discharge records on a daily basis to HQMS in an automated
manner. As of December 31, 2017, HQMS covered 31 provinces and
1037 Class 3 hospitals (44.3% of all Class 3 hospitals in China), captur-
ing the medical data of a total of 76 263 617 inpatients. The grade dis-
tribution (3A, 3B, 3C, or unclassified) of hospitals in HQMS was similar
to that of all Class 3 hospitals in China (Table S1). Class 3 hospitals are
the top tier of medical system in China with the minimum requirement
of 500 beds. In contrast to tertiary hospitals of western medical sys-
tem, Class 3 hospitals in China also provide primary and secondary
care as well as more specialist service. For each patient in Class 3 hos-
pitals, information on demographic characteristics, clinical and patho-
logical diagnoses, treatment procedures and expenditure breakdowns
were extracted from the standardized discharge summary known as
the “front-page” of hospital medical records. These records were
filed by the doctors in charge of the patients. The diagnoses were
then coded based on the International Classification of Diseases-10
(ICD-10) by certified coders in each hospital.
China Reinsurance Company (CRC) is the largest company in China
specializing in life insurance business. The CRC database included
93 123 018 commercial CII buyers from 2000 to 2016, accounting for
90% of commercial CII clients in China. Data in the CRC database
included demographic characteristics, clinical and pathological diagno-
ses, type of insurance and insurance claim data of clients.
The level of access to screening was assessed using the type of
medical insurances and per capita disposable income (PCDI) as indica-
tors. The three types of social medical insurances (RMI, URMI and
UEMI) cover different population groups. Individuals with UEMI gen-
erally have a steady job and their employers commonly offer opportu-
nities for annual health checks as a benefit. URMI is the basic social
medical insurance for unemployed adults, students, children and the
elderly in urban areas. RMI is the basic social medical insurance for
those living in rural areas. Data on PCDI, number of inpatients of
What's new?
In recent decades, the incidence of thyroid cancer has
increased rapidly worldwide. In China, the role of thyroid
cancer screening as part of regular health checks and poten-
tial overdiagnosis remain unclear. Moreover, there are con-
cerns among the general public that mandatory salt
iodization may have contributed to the epidemic of thyroid
cancer. Here, the authors found that the increase in thyroid
cancer in China is associated with increased access to health
care and screening, but not with salt iodization. Moreover,
the results suggest that approximately 1000 individuals are
overdiagnosed with thyroid cancer daily, calling for urgent
measures to prevent overdiagnosis.
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Class 3 hospitals and the population of China were extracted from
China Statistical Yearbook.19 Iodine is a necessary element for the
synthesis of thyroid hormones and mainly excreted through urine.
Median urinary iodine (MUI) has been recommended by international
authorities as an indicator of the iodine nutritional status in the popu-
lation.20 The MUI values of 31 provinces in China were obtained from
national IDD surveys in 1999, 2005 and 2011.21-23
The ICD-10 was used to identify patients with TC (code
C73).4,24 In HQMS, the first medical record with the diagnosis of
TC (including primary and nonprimary diagnosis) was identified to
be a new TC inpatient. Duplicated records of TC patients were
excluded in HQMS and CRC. We used the change of the standard-
ized proportion of TC inpatients among all inpatients in HQMS,25
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F IGURE 1 The proportion of TC inpatients with different social health insurances. The proportion of TC inpatients with different social
health insurances were standardized to the inpatients in HQMS by age and gender. A, The proportion of TC inpatients in HQMS with different
social health insurances from 2013 to 2017. B, The proportion of TC inpatients in all HQMS inpatients with three types of social health
insurances in different age groups. HQMS, Hospital Quality Monitoring System; TC, thyroid cancer
TABLE 1 Characteristics of TC patients in HQMS and CII buyers
Characteristic
TC patients
in HQMS Total HQMS
TC patients in
CII buyers Total CII buyers
N 512 270 76 263 617 96 181 93 123 018
Gender, N (%)
Male 120 309 (23.5) 34 378 476 (45.1) 19 490 (20.3) 46 355 364 (49.8)
Female 391 961 (76.5) 41 885 141 (54.9) 76 691 (79.7) 46 767 654 (50.2)
Age
Mean (SD) 45.6 (12.4) 47.6 (20.5) 44.9 (9.0) 32.1 (21.9)
Median (IQR) 46 (37, 54) 49 (32, 63) 45 (39, 51) 35 (25, 42)
Age distribution, N (%)
0-19 4423 (0.9) 6 249 963 (8.2) 396 (0.4) 18 143 444 (19.5)
20-44 233 551 (45.6) 25 596 350 (33.6) 46 204 (48.0) 58 427 477 (62.7)
45-64 241 383 (47.1) 27 086 258 (35.5) 49 011 (51.0) 16 532 801 (17.8)
≥65 32 913 (6.4) 17 331 046 (22.7) 568 (0.6) 19 296 (<0.1)
Pathology, N (%)a
PTC 278 406 (97.9) — — —
FTC 2871 (1.0) — — —
MTC 2681 (0.9) — — —
ATC 538 (0.2) — — —
Abbreviations: ATC, anaplastic thyroid cancer; CII, critical illness insurance; FTC, follicular thyroid cancer; HQMS, Hospital Quality Monitoring System; IQR,
interquartile range; MTC, medullary thyroid cancer; PTC, papillary thyroid cancer; TC, thyroid cancer.
a44.5% of pathology data were missing.
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standardized to the standard population of China in 2016 by age
and gender. The number of new TC patients in Class 3 hospitals
was calculated by the proportion of new TC patient times the over-
all number of inpatients of all Class 3 hospitals.26 The incidence of
TC in China was calculated by the number of new TC patients in
Class 3 hospitals divided by the total population of China, which
was also standardized to the standard population of China in 2016
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0                   10                  20                 30                 40                 50 0                   10                  20                 30                 40                 50
0                   10                  20                 30                 40                 50 0                   10                  20                 30                 40                 50
0               10              20             30              40              50              60 0               10              20             30              40              50              60
0               10              20             30              40              50              60 0               10              20             30              40              50              60
r = 0.54   P = 0.002 r = 0.64  P < 0.001
r = 0.53   P = 0.002 r = 0.53  P = 0.002
r = 0.63   P <0.001 r = 0.57   P = 0.001

















































































































































































































2013 Per Capita Disposable Income (¥1000) 2014 Per Capita Disposable Income (¥1000)
2013 Per Capita Disposable Income (¥1000) 2014 Per Capita Disposable Income (¥1000)
2015 Per Capita Disposable Income (¥1000) 2016 Per Capita Disposable Income (¥1000)






























































F IGURE 2 The correlation between the occurrence of TC and per capita disposable income. A-D, The relation between per capita disposable
income and the proportion of TC inpatients in HQMS at provincial level, for each of the 4 years between 2013 and 2016. E-H, The relation
between per capita disposable income and the incidence of TC in CII buyers at provincial level, for each of the 4 years between 2013 and 2016.
CII, critical illness insurance; HQMS, Hospital Quality Monitoring System; TC, thyroid cancer [Color figure can be viewed at
wileyonlinelibrary.com]
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2.2 | Statistical analysis
The incidence of TC in CII buyers had kept increasing since 2000 and
increased more rapidly since 2010. We conservatively estimated the
number of new TC patients via screening to make our conclusion
safer and more convinced. Therefore, we assumed that all the TC
patients diagnosed in 2010 were symptomatic and used the incidence
of TC in CII buyers as the “background” rate for TC incidence (ie, all
the patients were diagnosed after clinical presentations instead of
being detected via screening). The overdiagnosed cases of TC were
calculated by using the following approach: The number of over-
diagnosed TC patients = The number of new TC patients − The num-
ber of TC patients with symptoms (the incidence of TC in CII buyers
in 2010 * the population of China). We then forecasted the total num-
ber of newly diagnosed TC patients in 2019 to 2030 due to screening
according to two different predicted trends of changes in rate of diag-
nosis. The APC was calculated based on the number of new TC
patients between 2013 and 2017. Algorithm 1: If the current annual
(A)
    (1/1000)
(D)
    (1/1000)
(B)
    (1/1000)
(E)




   (1/1000)
r = - 0.10   P = 0.598 r = - 0.06   P = 0.753  
r = - 0.15   P = 0.434 r = - 0.11  P = 0.563  
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F IGURE 3 The relation between the occurrence of TC and iodine status. The relation between MUI in, A, 1999, B, 2005, C, 2011 and the
proportion of TC inpatients in HQMS from 2013 to 2017 at provincial levels. The relation between MUI in, D, 1999, E, 2005, F, 2011 and the
incidence of TC in CII buyers in 2016 at provincial levels. CII, critical illness insurance; HQMS, Hospital Quality Monitoring System; MUI, median
urinary iodine; TC, thyroid cancer [Color figure can be viewed at wileyonlinelibrary.com]
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rate of increase continues, we estimated the incidence of TC in each
group 2018 to 2030 using the following approach: Incidence in subse-
quent year = (Incidence in current year) + (Incidence in current year *
APC). Algorithm 2: If the rate of increase gradually slows down
followed by a moderate trend of decline, we estimated the incidence
of TC in each group using the following approach: 2017 to 2018—
same rate of increase as 2013 to 2017; 2018 to 2023—the rate of
increase gradually slows down to 0% (by 20% annual decrease
according to the APC of 2018); 2023 to 2030—5% annual decrease.
The specific APC of each year between 2018 and 2030 by Algorithm
2 was shown in Table S2.
Continuous data were presented as mean ± SD and median (inter-
quartile range [IQR]). Categorical variables were presented as number
(percentage) or proportions with 95% confidence interval (CI). CI was
calculated using Wald asymptotic confidence limits. The associations
between MUI and the proportion of TC inpatients in the HQMS, as well
as the incidence of TC in CII buyers were analyzed using Spearman Cor-
relation Coefficient. All P values are two-tailed. P value <.05 was con-
sidered to be significant. All statistical analyses were done with SAS
software, version 9.4 (SAS Institute, Inc., Cary, North Carolina).
3 | RESULTS
3.1 | General characteristics of the study
population
The characteristics of TC patients in HQMS from 2013 to 2017 and
in CII buyers from 2000 to 2016 were shown in Table 1. In total,
there were 512 270 inpatients with newly diagnosed TC in HQMS.
Approximately three quarters of these patients were female. Among
the pathological subtypes, papillary thyroid cancer (PTC) was
predominant (97.9%). In CRC database, 96 181 TC patients were
identified. The proportion of female TC patients was 79.7% in the
CRC database.
3.2 | TC and type of social health insurances
Figure 1A showed the proportion of TC inpatients in HQMS with
different types of social health insurances from 2013 to 2017. The
proportion among those with UEMI increased by 22.7% from 2013
(6.2/1000) to 2017 (7.6/1000). There was a small increase among
those with RMI (3.6%) and in those with URMI, the proportion actu-
ally dropped (−1.3%). Figure 1B showed the proportion of TC inpa-
tients in all HQMS inpatients with three types of social health
insurances in different age groups. The gap between the proportion
of TC inpatients in HQMS with different types of social health
insurances among those aged 30 to 55 was wider than those aged
over 55.
3.3 | The proportion of TC inpatients in HQMS in
different provinces and the relationship with income
and iodine status
There was a positive correlation between the proportion of TC inpa-
tients in HQMS and PCDI in different provinces in 2013, 2014, 2015,
2016, P < .01 (Figure 2A-D). The correlation coefficients were 0.48,
0.59, 0.45 and 0.48, respectively. Likewise, a positive correlation was
observed between the incidence of TC in CII buyers and PCDI in dif-
ferent provinces in 2013, 2014, 2015, 2016, P < .05 (Figure 2E-H).
The correlation coefficients were 0.55, 0.51, 0.44 and 0.37,
respectively.
(1/100,000)
The incidence of TC estimated by National Cancer Center in 2014 








































































F IGURE 4 The age and gender
standardized incidence of TC in China
and in CII buyers. The estimated
incidence of TC in China and in CII
buyers were standardized to the
population of China by age and
gender. The blue curve was the
incidence of TC in CII buyers between
2000 and 2016. The red curve
represented the estimated incidence
of TC in China between 2013 and
2017 based on the proportion of TC
of HQMS and the total number of
inpatients of Class 3 hospital. The
green dot was the incidence of TC
estimated by National Cancer Center
of China in 2014 by using data from
449 cancer registries5. CII, critical
illness insurance; HQMS, Hospital
Quality Monitoring System; TC,
thyroid cancer
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There was no correlation between the proportion of TC inpatients
from 2013 to 2017 and MUI in different provinces in 1999 and 2005,
P > .05 (Figure 3A,B). There was a negative correlation between the
proportion of TC inpatients in HQMS from 2013 to 2017 and MUI in
provinces in 2011, with a correlation coefficient of −0.42 (P < .05)
(Figure 3C). Similar associations were observed in the incidence of TC
in CII buyers in 2016 with MUI at provincial levels (Figure 3D-F), as
well as in 2012, 2013, 2014 and 2015 (Figures S1-S4).
3.4 | The incidence of TC in China
In CII buyers, the incidence of TC increased from 17.3/100 000 in
2013 to 27.2/100 000 in 2016. Based on the proportion of TC of
HQMS and the total number of inpatients of Class 3 hospital,20 the
increase in estimated incidence in China between 2013 and 2017 was
39.7% (23.9/100 000 to 33.4/100 000) (Figure 4). There were
432 635 new TC cases in 2017. Among these new cases, we estimated
that 85 154 cases were diagnosed with symptoms and 347 481 cases
were overdiagnosed due to screening (Table S3). In 2017, approxi-
mately 1000 individuals were overdiagnosed with TC daily.
3.5 | Burden from hospitalization of patients
with TC
The burden from TC was shown in Table 2. We estimated that there
were 1.98 million newly diagnosed TC inpatients among all Class 3
hospitals in China from 2013 to 2017, responsible for 19.7 million
days of hospital stays at an expense of 40.7 billion RMB.
3.6 | The estimated number of TC patients aged
20 to 64 between 2019 and 2030
The number of new TC patients aged 20 to 64 assuming no screen-
ing is estimated to be 1.0 million between 2019 and 2030 (Table S3).
If the current annual rate of increase continues, the estimated num-
ber of newly diagnosed TC patients would be 11.6 million. If the
rates of increase gradually slow down followed by a moderate trend
of decline, the figure would be 6.1 million. Therefore, without a
sharp reduction in screening activities, we forecast that 5.1 million
healthy individuals would be overdiagnosed with TC between 2019
and 2030.
4 | DISCUSSION
Using two national databases involving over 76 million inpatients and
93 million commercial CII buyers, our study indicated that the epi-
demic of TC in China was likely to be the result of increased access to
screening, and unlikely to be related with salt iodization. This rapid
rise of TC incidence brings a heavy disease burden.
Screening can identify TC which often exists as indolent, subclini-
cal lesions.27 In our study, TC occurs most frequently in people with
UEMI and the rate of increase was highest in this group compared
with those with URMI and RMI. A very sharp increase in incidence
was also observed in commercial CII buyers. The gap between the
proportion of TC inpatients in HQMS with different types of social
health insurances became narrowed at age over 55 and disappeared
at age over 60, which were the statutory retirement age of female
and male employees in China, respectively. That people with UEMI
and commercial CII have more access to health checks and screen-
ing13 was likely to be the main reason behind these observations. We
also found that income at provincial level was positively related to the
proportion of TC inpatients in HQMS in the province. The likely expla-
nation is that people with higher incomes are more likely to be
exposed to health checks offered by their employers or paid for out
of pocket, similar to what was found in the United States.7
There are concerns among the general public in China that the
rise in TC may have been the result of salt iodization.17,18 In our study,
iodine status was not associated with TC at provincial level. Since the
implementation of salt iodization policy in China, three national uri-
nary iodine sampling surveys were conducted in 1999, 2005 and
TABLE 2 Burden from hospitalization of patients with TC
Year 2013 2014 2015 2016 2017 2013-2017
Inpatients in HQMS (thousand) 11 982 17 903 19 769 21 963 20 355 76 264a
New TC inpatients in HQMS (thousand) 69 95 111 124 113 512
Cost (per admission, ¥) 18 409 19 675 20 876 21 835 21 135 20 611
Average hospital stays (days) 10.1 10.2 10.1 9.9 9.7 10.0
Total inpatients in all Class 3 hospitals (thousand) 54 501 62 910 68 289 76 862 83 960 —
Estimated new TC inpatients in all Class 3 hospitals(thousand)b 314 337 394 448 486 1979
Estimated total cost (¥, million) 5774 6638 8228 9778 10 268 40 686
Estimated total hospital stays (thousand days) 3168 3441 3981 4434 4713 19 737
Abbreviations: HQMS, Hospital Quality Monitoring System; TC, thyroid cancer.
aThe total inpatients in HQMS from 2013 to 2017 excluded medical records of repeated admission.
bAssumed that the distribution of Class 3 hospitals included in HQMS were identical to the distribution of all Class 3 hospitals in China, the number of new
TC patients in Class 3 hospitals was calculated by the proportion of new TC patients in HQMS times the overall number of inpatients of all Class 3
hospitals.
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2011, and salt iodine concentration was adjusted accordingly. From
1999 to 2011, the trend of MUI in China was decreasing, contrary to
the increasing trend of TC incidence.4 According to the iodine status
standards defined by WHO/UNICEF/ICCIDD, most of the provinces
in China were in the “adequate” (defined as MUI values 100-199 μg/L)
or “more than adequate” (defined as MUI values 200-299 μg/L)
iodine intake status. Only four provinces (Jiangsu, Jiangxi, Guizhou
and Anhui) were in the “excessive iodine intake status” category
(defined as MUI values ≥300 μg/L).23 Using HQMS data, we found
that the occurrence of TC in these four provinces was lower than the
national average. In Denmark, the incidence of TC had risen rapidly
before national iodine supplementation, and differences in iodine
intake did not affect TC incidence.28 Thus, salt iodination policy is
unlikely to be a driver of the rapid increase of TC in China.
'The sharp rise of TC diagnoses brought a heavy burden on
medical resources in China. The direct hospitalization expenses from
2013 to 2017 of TC patients in Class 3 hospitals of China was
40.7 billion RMB, which did not include the expenses for long-term
treatment and follow-up. In addition, the diagnosis and treatment of
TC could seriously impact the quality of life and mental health of
the individuals affected.29,30 Part of the TC patients had to accept
permanent thyroxine supplement and suffer from the side effects of
TC surgery (hypoparathyroidism, hypocalcemia and vocal cord or
fold paralysis).10
Our results suggested that previous studies have substantially
underestimated the incidence of TC in China. Two recent reports were
available from the National Cancer Center of China. The first one esti-
mated the incidence of TC in 2015 at 6.55/100 000 by applying age-
specific incidence rates from 72 cancer registries (2009-2011).4
Another report published in 2018 reported an estimated incidence of
12.40/100 000 in 2014, using data from 339 cancer registries.5 In our
study, we estimated that the number of new thyroid patients among
Class 3 hospitals in 2014 was 337 383. The incidence of TC of China
was estimated to be 24.9/100 000 for 2014, which were much higher
than the incidence published in the previous study.5
There is no evidence that screening for TC is effective in reducing
TC mortality. There has also been no randomized trial to evaluate the
effectiveness of screening.31 Contrast to the sharp rise of TC inci-
dence, the mortality of TC has remained low and stable in recent
decades.1,3 Roughly 50% of new-diagnosed TC are papillary thyroid
microcarcinoma,27 defined as a PTC ≤1 cm in diameter. The vast
majority of these lesions are indolent in nature and do not kill the
patients.10 Identifying these tumors by screening has almost certainly
been responsible for the apparent improvement in 5-year relative sur-
vival of TC in China and South Korea.32,33
Similar to other ecological investigations, our study has limita-
tions. In assessing the relationship between screening and TC diagno-
sis, we have used the type of medical insurances and PCDI as proxy
indicators of level of access to screening in our analyses. We believe
however that the much sharper surge in TC occurrence over a short
period among the population covered by UEMI compared to those
under the other two insurance schemes suggests strongly that a real
difference in disease risk of TC between the groups was highly
unlikely, and that higher access to screening was a much more plausi-
ble explanation. This is also supported by the positive correlation
between PCDI and TC occurrence at provincial level. Similarly, there
are potential problems of ecological analyses on the iodine question,
as provincial MUIs were also used to assess population iodine status
and we could not take into account potential confounders. However,
it is clear that provinces with up to three to four times higher total
iodine exposure than those with lowest exposure have not experi-
enced higher TC occurrence. If anything, there is actually some sug-
gestion that higher urinary iodine might be associated with lower rate
of diagnosis of TC. The conclusion that salt iodization was very
unlikely to be a factor behind the large rise of TC should therefore
be safe.
We concluded that the epidemic of TC in China was associated
with the increased access to health check, but not related to salt
iodization. The incidence of TC in China was also substantially
underestimated. Assuming a gradual slowing down of the rate of
increase followed by a moderate trend of decline, there would still
be approximately 5.1 million healthy men and women who would
become TC patients unnecessarily between 2019 and 2030. As a
reference, the estimated 5-year prevalence for all cancers combined
in 2011 in China was 7.49 million,34 and the total number of cancer
survivor globally was approximately 32 million in 2012.35 Previous
autopsy series showed that incidental TC lesions were identified in
4.7% to 35.6% of individuals who had no history of TC.27 Recently,
Li et al indicated that large numbers of TC were estimated to be
overdiagnosed, including China.36 The results of this hospital-based
study were broadly coherent with the population-based estimates.
Therefore, a clear guidance is urgently needed to prevent this vast
“reservoir” from being unearthed unnecessarily by uncontrolled
screening in China's efforts to achieve the objectives enshrined in
Healthy China 2030.37 Our findings may also provide an additional
cautionary note to other countries where similar health checks are
taking place.
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